Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Dr. Lippman's work has uncovered new means of treating and preventing several types of cancer through his research on molecular biology and carcinogenesis. His studies have also led to the development of molecular targeted drugs for cancer prevention, including trials for high-risk populations.
The Lance Armstrong Foundation has established an endowed chair in oncology at Indiana University, providing $1.5 million for research and program development. Dr. Einhorn, a renowned expert on urologic cancer, will lead the initiative to improve patient therapies and quality of life.
A study found that relatives of women with bilateral breast cancer and a normal CHEK2 gene are at a 23.8% risk by age 80, while those with the faulty variant have a 58.8% risk. Testing for the CHEK2*1100delC mutation in women with family history could be useful for predicting personal risks.
Researchers analyzed data from 79,994 women to evaluate associations of statins, lipid-lowering drugs, and serum cholesterol levels with breast cancer. No link was found between these factors and breast cancer risk.
Researchers analyzed medication orders from outpatient clinics and found a three percent overall error rate and two percent serious error rate. Most errors were due to omitted dosages or incorrect orders, but serious harm was avoided by existing checks in most cases.
Researchers found that 3% of medication orders contained errors, with 60% of pediatric errors and 82% of adult errors having potential to harm patients. Hospitals implemented changes to their automated drug order-entry systems to reduce future errors.
Researchers discovered that endothelial cells lack the transport protein used by tumours to eject foreign molecules, making them vulnerable to anti-cancer drug GSAO. This breakthrough could lead to more effective treatment strategies against various tumour types.
A new treatment approach using topotecan and carboplatin eliminates the need for etoposide, reducing the risk of leukemia. The study also suggests that vincristine contributes little to treating retinoblastoma, making it a promising alternative.
A recent study published in Nature Medicine reveals the importance of antigen-presenting cells in the graft-versus-leukemia effect, which occurs during bone marrow transplants. The discovery has significant implications for improving cellular immunotherapy and making it safer and more effective for cancer patients.
The new drug dnaJP1, derived from a naturally occurring protein dnaJ, has been found to be effective in treating rheumatoid arthritis by re-educating the immune system's tolerance to the amino acid sequence. In a double-blind trial, patients receiving dnaJP1 experienced lessening of symptoms and improvement in mobility.
The USC TREC Center will investigate how to prevent cancer by controlling obesity in children and adolescents, with a focus on high-risk ethnic groups.
Scientists found a gene named vav-1 that controls the timing of basic activities in nematode worms, including swallowing food, laying eggs, and defecating. The gene is related to human genes linked to cancer, suggesting it may be used to develop new treatments.
Researchers discovered that a specific gene variant can arise as a mutation during cancer development, contributing to tumor growth and spread. The study found the variant in nearly half of liver metastatic tumors, suggesting it may be an important target for new therapies.
Researchers found that NSAIDs reduced oral cancer risk by 53% in smokers and active users. However, long-term use of NSAIDs doubled the relative risk of death due to heart disease.
The new center aims to develop nanomaterials and nanodevices for cancer diagnostics, therapeutics, drug delivery, imaging, and monitoring applications. Researchers will focus on developing early detection tools, targeting cancer cells with chemotherapeutic agents, and creating new classes of drugs.
The School of Medicine will research and apply nanotechnology for the diagnosis and treatment of cancer. The nanotechnology offers several advantages, including precise targeting of tumor cells and drug therapies.
Gleevec has been found to reverse lung vascular remodeling and pulmonary hypertension in experimental models. Larger clinical trials are planned to test its safety and effectiveness.
Researchers at the University of Oxford discovered a family of amino acid transporters that promote cell growth when overexpressed in fruit flies, leading to excessive growth and tumour development. The findings suggest human equivalents of these genes may be involved in cancer, paving the way for potential new treatments.
Renal transplant recipients are 3.6 times more likely to develop melanoma than the general population, with a mortality rate up to 6 percent in some regions. Men who have had a kidney transplant face the greatest risk, and risk increases rapidly with age.
The NIH has renewed a network focused on understanding how genes influence drug responses, aiming to create personalized therapies with fewer side effects. The network will explore various genetic factors affecting medication efficacy and toxicity across nine NIH components.
Researchers found that farnesyl transferase inhibitors can normalize abnormal nuclei in progeria cells. The treatment targets a genetic mutation causing lamin A protein production issues.
A recent study has identified a molecular pathway linked to breast cancer recurrence, suggesting that the transcriptional repressor Snail may play a role in progression. Genetic screening of human breast cancer samples revealed that high levels of Snail expression predict decreased relapse-free survival.
Researchers have identified two ADAMTS genes, ADAMTS8 and ADAMTS15, that can help predict disease outcome in breast cancer patients. The study reveals four categories of risk based on gene activity levels, with those in the highest risk category three times more likely to experience recurrence.
Researchers found that the drug combination increased stem cell mobilization in 25 patients, reducing the number of necessary stem cell collections. This can lead to more successful transplantations and faster recovery for cancer patients.
A recent study confirms that letrozole treatment can improve the survival of women with node-positive disease and reduce metastasis risk. The study also found a 39% reduction in the risk of metastasis among participants receiving letrozole.
Researchers found that women taking letrozole experienced a significantly better overall disease-free survival rate and distant disease-free survival rate compared to those on placebo. This study confirms the protective effect of extended adjuvant letrozole therapy for postmenopausal breast cancer patients.
Researchers discover Chk1 protein plays natural defense against therapeutic damage in cancer cells, making treatment less effective. Combining chemotherapy agents with Chk1 inhibitors may increase efficacy and overcome clinical resistance.
A new study by Kishan Pandya and colleagues found that gabapentin significantly reduced hot flash severity scores in women with breast cancer. The results suggest that gabapentin can be added to the list of non-hormonal agents for controlling hot flashes in these patients, with further studies needed on higher doses.
A Stanford study found that combining vitamin D and nonsteroidal anti-inflammatory drugs (NSAIDs) suppresses prostate cancer growth more effectively than using either drug alone. The researchers discovered a 25-70% reduction in cell growth when calcitriol was used with NSAIDs, with potential implications for new treatment options.
Researchers develop stealth particles to deliver chemotherapy drugs to tumors, reducing phagocytosis by 24% in cell culture. The system allows for targeted delivery of lower doses, potentially improving cancer treatment outcomes.
Researchers identify six distinct p53 isoforms in human cells, revealing their potential role in modulating tumor suppressor activity and cell death. These findings may help identify patients at risk of developing aggressive cancer and inform personalized drug therapy.
Researchers at IRCM discover EAT-2 suppresses NK cell activity, boosting killer function to combat cancers and infections. Medications inhibiting EAT-2 may improve treatment effectiveness for cancers and communicable diseases.
The National Foundation for Cancer Research (NFCR) and the Prostate Cancer Foundation have partnered with the Burnham Institute to develop a 3D culture system that simulates tumor microenvironments. This technology enables rapid testing of candidate drugs and has potential applications beyond cancer research.
Researchers have found a way to get drugs past the blood-brain barrier to treat brain cancer. The compound JV-1-36, an antagonist of the hypothalamic growth hormone-releasing hormone, has shown promising results in treating malignant glioblastomas.
New study reveals that only about two-thirds of phase I clinical trial data were published within 7.5 years, highlighting the need for improvement in data dissemination. Lack of time and author relocation were cited as major obstacles to publication.
Researchers found that gefitinib was more effective at inhibiting cell growth and increasing apoptosis in NSCLC cells with mutant EGFR. In contrast, cetuximab showed no significant response in patients with EGFR mutations.
Researchers found that gefitinib (Iressa) was significantly effective in treating lung cancer cells containing a mutant EGFR molecule, while cetuximab (Erbitux) had little effect. The study suggests that mutations in the targets of designer drugs critically influence their effectiveness.
Researchers found that combining interferon with irinotecan boosts IRF5 protein levels in colon cancer cells, leading to increased cell death. The combination therapy may limit side effects and make it harder for cancer cells to build resistance.
Researchers have found that nearly 42% of ovarian cancer patient tumor tissues contain alterations in the protein km23. This discovery suggests km23 as a possible diagnostic indicator and therapeutic target for ovarian cancer. Further studies aim to develop a screening test and targeted therapies using km23.
A study published by Cedars-Sinai Medical Center has identified the EMP-1 protein as a biomarker for resistance to gefitinib, a targeted cancer drug used to treat non-small-cell lung cancer. The research found that EMP-1 is present in tumors of patients who fail to respond to treatment with gefitinib.
A team of UW-Madison scientists has developed a technique to easily manipulate and exchange the sugars found in chemicals produced in nature. This breakthrough could lead to the development of new anti-cancer treatments by allowing researchers to rapidly scan the roles of different sugars in complex natural products.
A study published in Developmental Cell reveals that connective tissue holding a cancer cell in place degrades, allowing it to spread to other parts of the body. The researchers identified a specific pathway critical for cancer cell activity, which could lead to more effective drug therapies with reduced side effects.
A new study has identified a protein called DOCK180 that senses chemicals inducing cell migration. This finding may lead to treatments halting cancer metastasis and immune disorders like arthritis and asthma by inhibiting inappropriate cell movement.
A recent study published in The Lancet found that a single dose of chemotherapy is comparable to radiotherapy in treating stage 1 seminoma. Patients who received chemotherapy had fewer seminomas occurring in their remaining testicle and were less likely to develop tumors.
A trial involving 731 patients found that treatment with erlotinib resulted in longer survival compared to a placebo, with patients on erlotinib surviving an average of 6.7 months versus 4.7 months. Erlotinib was also well-tolerated and improved physical function, quality of life, and symptoms.
Researchers identified a specific amino acid modification in Keap1 as the critical step that triggers increased Nrf2 and protective protein production, potentially leading to cancer prevention. The study's findings suggest that targeting this amino acid could lead to new cancer-fighting drugs.
Researchers have developed a novel inhibitor, SB-3CT, that protects against brain damage in mice undergoing a stroke. The treatment reduces brain damage to 30% and preserves neurological function, offering potential for new stroke treatments.
Researchers at USC discovered that anti-angiogenesis drugs increase glucose regulated protein 78 levels, blocking cell death and leading to drug resistance. Suppressing GRP78 gene expression can overcome resistance to chemotherapy drug etoposide.
Researchers discovered that griseofulvin inhibits cancer cell growth by affecting mitosis, potentially providing a therapeutic advantage when combined with other treatments. The drug has been used for decades to treat fungal infections and shows mild anti-cancer activity.
Researchers found that Gleevec, a cancer drug, slowed the spread of poxviruses in mice. The study suggests that Gleevec might be useful as a preventative against adverse effects of smallpox vaccine.
A two-year project at the University of Edinburgh aims to understand the cultural practices and needs of Sikh and Muslim patients nearing the end of life. The study will explore how caregivers can better support these communities, highlighting the importance of transcultural training for healthcare professionals.
Researchers at USF have discovered a tailored therapy for tumors with high levels of active Akt, which is abundant in 40% of women with ovarian cancer. The compound tricirbine has been found to inhibit some cancers and will be tested in clinical trials starting within six to eight months.
Research reveals that an individual's genetic makeup determines how arsenic is metabolized, affecting disease risk. The study found a specific gene variant associated with altered urinary arsenic metabolites in children, but not adults.
Scientists at Sanford Burnham Prebys Institute have identified three lead compounds that inhibit anthrax lethal factor (LF) with high potency and selectivity. The compounds, when combined with antibiotics like Ciprofloxacin, showed a two-fold increase in survival rate for mice infected with anthrax spores.
Researchers developed mathematical model to estimate probability of drug-resistant mutant cells and identify optimal combination of three drugs. The model suggests a 'cocktail' approach is needed to reduce treatment failure rates, improving outcomes for patients with CML.
Researchers have made advances in nuclear medicine, providing alternatives to traditional chemotherapy treatment for non-Hodgkin's lymphoma patients. The new treatments showed improved response rates and durations, exceeding those following chemotherapy, and offer a personalized dose option.
David M. Goldenberg, a pioneer in radiolabeled antibodies, has received the Society of Nuclear Medicine's 2005 Paul C. Aebersold Award. He has developed antibodies for various cancer types and therapies, making significant contributions to nuclear medicine.
The Burnham Institute will screen 2 million compounds against 20 disease targets per year, revealing specific compounds that interact with and inhibit disease-causing proteins. The new capabilities will accelerate the discovery of novel medicines for various diseases.
Fine-tuning drug levels in neuroblastoma patients can improve treatment outcomes, according to St. Jude researchers. By closely monitoring and adjusting topotecan levels, the study demonstrates that pharmacokinetic-based dosing can tailor cancer treatment to individual children, potentially increasing long-term survival rates.
Researchers at UNC Chapel Hill found that radiation exposure at older ages significantly increases the risk of lung cancer among Hanford nuclear workers. The study analyzed data from 26,389 workers hired between 1944 and 1978 and identified 2,265 cancer deaths.